Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01518465 · ClinicalTrials.gov registry record · Phase 2
Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma
A Phase 2 study, sponsored by University of Southern California.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT01518465 is a Phase 2 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 13 participants.
The verdict
NCT01518465, a Phase 2 study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
This randomized pilot phase II trial studies how well giving dalteparin, lenalidomide, and low-dose dexamethasone together works in treating patients with previously untreated multiple myeloma. Anticoagulants, such as dalteparin, may help prevent blood clots from forming in patients being treated with lenalidomide and dexamethasone for multiple myeloma. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving dalteparin, lenalidomide, and dexamethasone together may be an effective treatment for multiple myeloma
Interventions
- OTHER laboratory biomarker analysis
- DRUG dexamethasone
- DRUG lenalidomide
- DRUG dalteparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2012-01-09 |
| Est. Completion | 2017-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01518465
The ClinicalTrials.gov registry entry for NCT01518465 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01518465 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01518465 about?
NCT01518465 is a clinical study titled "Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma". This randomized pilot phase II trial studies how well giving dalteparin, lenalidomide, and low-dose dexamethasone together works in treating patients with previously untreated multiple myeloma. Anticoagulants, such as dalteparin, may help prevent blood clots from forming in patients being treated wi...
What is the current status of trial NCT01518465?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2012-01-09. Estimated completion is 2017-10-31.
What interventions are being tested in trial NCT01518465?
The interventions under investigation include: laboratory biomarker analysis (OTHER), dexamethasone (DRUG), lenalidomide (DRUG), dalteparin (DRUG).
Who is sponsoring clinical trial NCT01518465?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.